Poongjeon Pharmacy풍전약품

Poongjeon Pharmacy shows deep losses and a shrinking share price, and has just announced a new share issuance.

The company reports trailing twelve-month revenue of ₩29.7B but operating losses of ₩4.7B and net losses of ₩5.7B as of H1 2026, with free cash flow at -₩5.7B. The shares closed at ₩2,230 on 2026-10-27, down 58.3% over one year and near the low end of their 52-week range. The company profile describes stem cell therapy development alongside cosmetics sales, though the data does not give a breakdown of revenue by segment.

What stands out

• Revenue rose sharply in 2025 to ₩3.6B from ₩0.8B in 2024, but operating losses of ₩4.7B were still far larger than revenue.
• Cash of ₩4.8B exceeds borrowings of ₩3.8B, but free cash flow over the last twelve months was -₩5.7B, so the cash balance is being drawn down.
• The company has filed multiple convertible bond and third-party allotment issues in 2026, and a conversion price adjustment on its 2nd series in August.
• Foreign ownership fell from 2.0% to 1.6% over the last 60 days, and recent 20-day investor flows show retail buying with foreign selling.
• Valuation shows a price-to-book ratio of 0.7 and no earnings-based multiples, since earnings are negative; the data gives no analyst ratings or price targets.

What to watch

• A ₩3B third-party allotment rights offering was announced on 2026-10-26; the size of dilution and pricing terms are not yet in the data.
• Full-year 2026 results, which are not yet in the data, will show whether operating losses are narrowing.
• The planned pharmaceutical wholesale business starting April 2026 is described but its financial contribution is not disclosed in the data.